Results 101 to 110 of about 28,823 (297)

Sexual Safety Signals of Common Antidiabetic Drugs: Insights From FAERS Disproportionality Analysis

Andrology, EarlyView.
ABSTRACT Background Erectile dysfunction is a prevalent and distressing complication of diabetes mellitus that markedly affects quality of life in male patients. Although the role of diabetes in erectile dysfunction is well‐established, potential drug‐induced sexual dysfunction associated with commonly prescribed antidiabetic medications remains ...
Shan Lin, Xuefeng Ding, Xin Dang, Qingyuan Zhan   +3 more
wiley   +1 more source

Time to exacerbation of heart failure is longer in Malaysian population on dipeptidyl peptidase-4 inhibitor

Heart India, 2017
Context: Diabetes mellitus is a recognized risk factor for heart failure. Dipeptidyl peptidase-4 inhibitors (DPP4i) are used in patients with diabetes largely due to its efficacy in glycated hemoglobin (HbA1c) reduction, neutral weight effect, and lower ...
J Hasan, R Najme Khir, M A Saman, K S Ibrahim, J R Ismail, R A Ghani, C W Lim, Z Ibrahim, E A Rahman, N Chua, HAZ Abidin, MKM Arshad, S Kasim   +12 more
doaj   +1 more source

Family C1 cysteine proteases: Biological diversity or redundancy? [PDF]

, 2003
Recent progress in the identification and partial characterization of novel genes encoding cysteine proteases of the papain family has considerably increased our knowledge of this family of enzymes.
M\ue9nard, Robert, N\ue4gler, Dorit K., Nägler, D. K., Ménard, R.   +3 more
core   +1 more source

Timing and duration of glucagon‐like peptide‐1 receptor agonist use and risk of nonarteritic anterior ischaemic optic neuropathy

Acta Ophthalmologica, EarlyView.
Abstract Purpose To investigate the association between glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) use and nonarteritic anterior ischaemic optic neuropathy (NAION) in type 2 diabetes, examining treatment recency and cumulative duration. Methods This nationwide registry‐based nested case–control study utilizedz Danish health registries (1996 ...
Siar Niazi, Filip Gnesin, Baker Nawfal Jawad, Zia Niazi, Puriya Daniel Wuertz Yazdanfard, Anne P. Toft‐Petersen, Kathrine Kold Sørensen, Amani Meaidi, Yousif Subhi, Christian Torp‐Pedersen   +9 more
wiley   +1 more source

Teneligliptin in management of type 2 diabetes mellitus

Diabetes, Metabolic Syndrome and Obesity, 2016
Surendra Kumar Sharma,1 A Panneerselvam,2 KP Singh,3 Girish Parmar,4 Pradeep Gadge,5 Onkar C Swami6 1Diabetes, Thyroid and Endocrine Centre, Galaxy Speciality Centre, Jaipur, 2Aruna Diabetes Centre, Chennai, 3Fortis Hospital, Sector 62, Phase VIII ...
Sharma SK, Panneerselvam A, Singh KP, Parmar G, Gadge P, Swami OC   +5 more
doaj  

Dipeptidyl peptidase-4-mediated fibronectin processing evokes a pro-fibrotic extracellular matrix [PDF]

Fibronectin serves as a platform to guide and facilitate deposition of collagen and fibrillin microfibrils. During development of fibrotic diseases, altered fibronectin deposition in the extracellular matrix (ECM) is generally an early event. After this,
Reinhardt, Dieter P., Dengjel, Jörn, Sengle, Gerhard, Antonyan, Alvard, Nyström, Alexander, Nelea, Valentin, Bornert, Olivier, Sharoyan, Svetlana, Zeyer, Karina, Bruckner-Tuderman, Leena, Bao, Xinyi, Leytens, Alexandre   +11 more
core   +1 more source

The effects of dipeptidyl peptidase-4 inhibition on microvascular diabetes complications. [PDF]

, 2014
We performed a review of the literature to determine whether the dipeptidyl peptidase-4 inhibitors (DPP4-I) may have the capability to directly and positively influence diabetic microvascular complications.
Angelo Avogaro, FADINI, GIAN PAOLO, AVOGARO, ANGELO, Gian Paolo Fadini   +3 more
core   +1 more source

Secular Trend in Glycaemic Management in Type 2 Diabetes Patients With and Without Cirrhosis Between 2000 and 2023: A Territory‐Wide Cohort Study

Alimentary Pharmacology &Therapeutics, EarlyView.
In this territory‐wide cohort study, improving glycemic control can be observed regardless of cirrhosis status. Oral antidiabetic medication was more often used in the non‐cirrhosis group, and insulin was preferred in patients with decompensated cirrhosis, who exhibited an increasing incidence of hypoglycemia over the years and need individualized ...
Mary Yue Wang, Sherlot Juan Song, Nana Peng, Grace Lai‐Hung Wong, Vincent Wai‐Sun Wong, Jimmy Che‐To Lai, Terry Cheuk‐Fung Yip   +6 more
wiley   +1 more source

Which is better, high‐dose metformin monotherapy or low‐dose metformin/linagliptin combination therapy, in improving glycemic variability in type 2 diabetes patients with insufficient glycemic control despite low‐dose metformin monotherapy? A randomized, cross‐over, continuous glucose monitoring‐based pilot study

Journal of Diabetes Investigation, 2019
Aims/Introduction The present study investigated the effect of high‐dose metformin or low‐dose metformin/linagliptin combination therapy on glycemic variability (GV) in type 2 diabetes patients with insufficient glycemic control despite low‐dose ...
Hiroshi Takahashi, Rimei Nishimura, Daisuke Tsujino, Kazunori Utsunomiya   +3 more
doaj   +1 more source

Targeting protein–protein interactions with reversible covalent modalities: Non‐cysteine chemistries

British Journal of Pharmacology, EarlyView.
Abstract Protein–protein interactions (PPIs) are central to diverse cellular functions, and represent a rapidly expanding class of therapeutic targets. Advancements in covalent drug design have enabled small‐molecule drugs to overcome challenges associated with engaging these targets, such as limited durations of action and difficult‐to‐drug (expansive,
Ruchira Basu, Steven Fletcher
wiley   +1 more source